Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis

Front Immunol. 2023 Jun 22:14:1203506. doi: 10.3389/fimmu.2023.1203506. eCollection 2023.

Abstract

Background: Dysregulated complement activation, increased protein citrullination, and production of autoantibodies against citrullinated proteins are hallmarks of rheumatoid arthritis (RA). Citrullination is induced by immune cell-derived peptidyl-Arg deiminases (PADs), which are overactivated in the inflamed synovium. We characterized the effect of PAD2- and PAD4-induced citrullination on the ability of the plasma-derived serpin C1-inhibitor (C1-INH) to inhibit complement and contact system activation.

Methods: Citrullination of the C1-INH was confirmed by ELISA and Western blotting using a biotinylated phenylglyoxal probe. C1-INH-mediated inhibition of complement activation was analyzed by C1-esterase activity assay. Downstream inhibition of complement was studied by C4b deposition on heat-aggregated IgGs by ELISA, using pooled normal human serum as a complement source. Inhibition of the contact system was investigated by chromogenic activity assays for factor XIIa, plasma kallikrein, and factor XIa. In addition, autoantibody reactivity to native and citrullinated C1-INH was measured by ELISA in 101 RA patient samples.

Results: C1-INH was efficiently citrullinated by PAD2 and PAD4. Citrullinated C1-INH was not able to bind the serine protease C1s and inhibit its activity. Citrullination of the C1-INH abrogated its ability to dissociate the C1-complex and thus inhibit complement activation. Consequently, citrullinated C1-INH had a decreased capacity to inhibit C4b deposition via the classical and lectin pathways. The inhibitory effect of C1-INH on the contact system components factor XIIa, plasma kallikrein, and factor XIa was also strongly reduced by citrullination. In RA patient samples, autoantibody binding to PAD2- and PAD4-citrullinated C1-INH was detected. Significantly more binding was observed in anti-citrullinated protein antibody (ACPA)-positive than in ACPA-negative samples.

Conclusion: Citrullination of the C1-INH by recombinant human PAD2 and PAD4 enzymes impaired its ability to inhibit the complement and contact systems in vitro. Citrullination seems to render C1-INH more immunogenic, and citrullinated C1-INH might thus be an additional target of the autoantibody response observed in RA patients.

Keywords: ACPA; C1-inhibitor; PAD; citrullination; complement system; rheumatoid arthritis; synovial fluid.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid*
  • Autoantibodies
  • Citrullination*
  • Factor XIIa / metabolism
  • Factor XIa
  • Humans
  • Plasma Kallikrein / metabolism
  • Protein-Arginine Deiminases / genetics
  • Proteins / metabolism

Substances

  • Protein-Arginine Deiminases
  • Factor XIIa
  • Plasma Kallikrein
  • Factor XIa
  • Proteins
  • Autoantibodies

Grants and funding

This work was supported by the Swedish Research Council (Grant 2018-02392), Reumatikerförbundet, the Österlund Foundation, the Kock Foundation, King Gustaf V’s 80th Anniversary Foundation, The Lars Hierta Memorial Foundation, The Royal Physiographic Society in Lund, Stiftelsen Professor Nanna Svartz Fond, Längmanska Kulturfonden, and Anna-Greta Crafoord’s Foundation, as well as grants for clinical research from ALF and Skåne University Hospital. EB was supported by a grant from National Science Center (UMO-2018/30/M/NZ1/00367). JP acknowledges support by grants from US NIH/NIDCR (DE 022597 and DE DE030939) and National Science Center (UMO-2018/30/A/NZ5/00650, NCN, Krakow, Poland). CS and JE acknowledge support from Novo Nordisk Foundation (BIO-MS) (NNF18OC0032724).